NICE guidance on inclisiran should be reconsidered
The National Institute for Health and Care Excellence (NICE) recently published draft guidance recommending inclisiran, a new cholesterol lowering drug, for selected patient groups.1 The director of…
Read Original Article: NICE guidance on inclisiran should be reconsidered »
